278 related articles for article (PubMed ID: 2571712)
1. CI-943, a potential antipsychotic agent. I. Preclinical behavioral effects.
Heffner TG; Downs DA; Meltzer LT; Wiley JN; Williams AE
J Pharmacol Exp Ther; 1989 Oct; 251(1):105-12. PubMed ID: 2571712
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological profile of the dopamine partial agonist, (+/-)-PD 128483 and its enantiomers.
Meltzer LT; Caprathe BW; Christoffersen CL; Corbin AE; Jaen JC; Ninteman FW; Pugsley TA; Serpa KA; Shih YH; Whetzel SZ
J Pharmacol Exp Ther; 1993 Sep; 266(3):1177-89. PubMed ID: 8103791
[TBL] [Abstract][Full Text] [Related]
3. CI-1007, a dopamine partial agonist and potential antipsychotic agent. II. Neurophysiological and behavioral effects.
Meltzer LT; Christoffersen CL; Corbin AE; Ninteman FW; Serpa KA; Wiley JN; Wise LD; Heffner TG
J Pharmacol Exp Ther; 1995 Aug; 274(2):912-20. PubMed ID: 7636754
[TBL] [Abstract][Full Text] [Related]
4. L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests.
Bristow LJ; Collinson N; Cook GP; Curtis N; Freedman SB; Kulagowski JJ; Leeson PD; Patel S; Ragan CI; Ridgill M; Saywell KL; Tricklebank MD
J Pharmacol Exp Ther; 1997 Dec; 283(3):1256-63. PubMed ID: 9400001
[TBL] [Abstract][Full Text] [Related]
5. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents.
Millan MJ; Brocco M; Rivet JM; Audinot V; Newman-Tancredi A; Maiofiss L; Queriaux S; Despaux N; Peglion JL; Dekeyne A
J Pharmacol Exp Ther; 2000 Jan; 292(1):54-66. PubMed ID: 10604931
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological characterization of PD 118717, a putative piperazinyl benzopyranone dopamine autoreceptor agonist.
Pugsley TA; Christofferson CL; Corbin A; DeWald HA; Demattos S; Meltzer LT; Myers SL; Shih YH; Whetzel SZ; Wiley JN
J Pharmacol Exp Ther; 1992 Dec; 263(3):1147-58. PubMed ID: 1361570
[TBL] [Abstract][Full Text] [Related]
7. CI-943, a potential antipsychotic agent. II. Neurochemical effects.
Pugsley TA; Coughenour LL; Myers SL; Shih YH; Courtland GG; Berghoff W; Stewart SF
J Pharmacol Exp Ther; 1989 Oct; 251(1):113-22. PubMed ID: 2571713
[TBL] [Abstract][Full Text] [Related]
8. The adenosine A2A receptor agonist CGS 21680 exhibits antipsychotic-like activity in Cebus apella monkeys.
Andersen MB; Fuxe K; Werge T; Gerlach J
Behav Pharmacol; 2002 Dec; 13(8):639-44. PubMed ID: 12478214
[TBL] [Abstract][Full Text] [Related]
9. PD 158771, a potential antipsychotic agent with D2/D3 partial agonist and 5-HT(1A) agonist actions. II. Preclinical behavioral effects.
Corbin AE; Meltzer LT; Ninteman FW; Wiley JN; Christoffersen CL; Wustrow DJ; Wise LD; Pugsley TA; Heffner TG
Neuropharmacology; 2000 Apr; 39(7):1211-21. PubMed ID: 10760363
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
Chipkin RE; Iorio LC; Coffin VL; McQuade RD; Berger JG; Barnett A
J Pharmacol Exp Ther; 1988 Dec; 247(3):1093-102. PubMed ID: 2905002
[TBL] [Abstract][Full Text] [Related]
11. CI-943, a potential antipsychotic agent. III. Evaluation of effects on dopamine neuronal activity.
Meltzer LT; Christoffersen CL; Heffner TG; Freeman AS; Chiodo LA
J Pharmacol Exp Ther; 1989 Oct; 251(1):123-30. PubMed ID: 2571714
[TBL] [Abstract][Full Text] [Related]
12. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
[TBL] [Abstract][Full Text] [Related]
13. WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity.
Marquis KL; Sabb AL; Logue SF; Brennan JA; Piesla MJ; Comery TA; Grauer SM; Ashby CR; Nguyen HQ; Dawson LA; Barrett JE; Stack G; Meltzer HY; Harrison BL; Rosenzweig-Lipson S
J Pharmacol Exp Ther; 2007 Jan; 320(1):486-96. PubMed ID: 17038512
[TBL] [Abstract][Full Text] [Related]
14. The neurosteroid 3 alpha-hydroxy-5 alpha-pregnan-20-one affects dopamine-mediated behavior in rodents.
Khisti RT; Deshpande LS; Chopde CT
Psychopharmacology (Berl); 2002 May; 161(2):120-8. PubMed ID: 11981591
[TBL] [Abstract][Full Text] [Related]
15. Neuropsychopharmacological profile of remoxipride in comparison with clozapine.
Skuza G; Rogóz Z; Wieczorek A
Pol J Pharmacol; 1997; 49(1):5-15. PubMed ID: 9431546
[TBL] [Abstract][Full Text] [Related]
16. DuP 734 [1-(cyclopropylmethyl)-4-(2'(4''-fluorophenyl)-2'- oxoethyl)piperidine HBr], a potential antipsychotic agent: preclinical behavioral effects.
Cook L; Tam SW; Rohrbach KW
J Pharmacol Exp Ther; 1992 Dec; 263(3):1159-66. PubMed ID: 1361571
[TBL] [Abstract][Full Text] [Related]
17. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
Perrault G; Depoortere R; Morel E; Sanger DJ; Scatton B
J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics.
Bardin L; Auclair A; Kleven MS; Prinssen EP; Koek W; Newman-Tancredi A; Depoortère R
Behav Pharmacol; 2007 Mar; 18(2):103-18. PubMed ID: 17351418
[TBL] [Abstract][Full Text] [Related]
19. Seroquel: behavioral effects in conventional and novel tests for atypical antipsychotic drug.
Migler BM; Warawa EJ; Malick JB
Psychopharmacology (Berl); 1993; 112(2-3):299-307. PubMed ID: 7871034
[TBL] [Abstract][Full Text] [Related]
20. Roxindole: psychopharmacological profile of a dopamine D2 autoreceptor agonist.
Bartoszyk GD; Harting J; Minck KO
J Pharmacol Exp Ther; 1996 Jan; 276(1):41-8. PubMed ID: 8558454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
